South Korean drug manufacturer HK inno.N has achieved a significant milestone by securing the world's inaugural Environmental Product Declaration (EPD) for an oral finished pharmaceutical product. The certification was awarded to the company's 50mg K-CAB tablet, a treatment designed for gastroesophageal reflux disease. The official presentation of the EPD certificate took place during a ceremony held in Oslo, Norway. An EPD serves as a standardized assessment that quantifies the environmental footprint of a product across its entire life cycle. By undergoing this rigorous third-party verification process, the company ensures that its environmental impact data is transparent and adheres to recognized international benchmarks. This development highlights a growing trend in the pharmaceutical industry toward prioritizing sustainability and environmental accountability in the production and life cycle management of medical treatments.
Source : The Korea Herald
Photo : The Korea Herald
